Skip to main content
Evome Medical Technologies Inc. logo

Evome Medical Technologies Inc. — Investor Relations & Filings

Ticker · EVMT ISIN · CA30053H1055 TSXV Manufacturing
Open in API
Filings indexed 403 across all filing types
Latest filing 2024-09-28 Regulatory Filings
Country CA Canada
Listing TSXV EVMT

About Evome Medical Technologies Inc.

https://www.evomemedical.com

Evome Medical Technologies Inc. is a medical device enterprise dedicated to the design, development, production, and distribution of specialized medical devices. The company's core business centers on human performance and rehabilitative solutions, specifically addressing the post-operative and recovery market. Evome aims to enhance patient outcomes through its portfolio of devices utilized in rehabilitation settings.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Regulatory Filings
2024-09-28 English
News release - English.pdf
Investor Presentation Classification · 95% confidence The document is a corporate presentation highlighting a growth plan and announcing a conference call to discuss Q2 2024 financial results. It includes strategic priorities, market reach, and acquisition plans but does not contain actual financial statements or detailed financial analysis. The document is a presentation aimed at investors and stakeholders, focusing on company strategy and market positioning rather than a formal financial report. Therefore, it fits the category of an Investor Presentation (IP). The document length is over 5,000 characters and contains substantive content, not just an announcement of a report publication or a certification, so it is not an RPA or RNS.
2024-08-15 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Evome Medical Technologies' second quarter 2024 financial results, including revenue, EBITDA, debt reduction, and business restructuring updates. It also announces a conference call to discuss these results. The presence of comprehensive financial data for the quarter ended June 30, 2024, including revenue, gross profit, adjusted EBITDA, and management commentary, indicates this is a quarterly financial report. The document is lengthy (over 12,000 characters) and contains substantive financial data and analysis, not just a brief earnings highlight or a simple announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an earnings release (ER) because it includes detailed financial statements and management discussion. It is not a report publication announcement (RPA) because the full financial data is included, not just a notice of availability. Hence, the correct classification is IR with high confidence. Q2 2024
2024-08-12 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements For the three and six months ended June 30, 2024 and 2023' and is marked as unaudited. It contains detailed financial statements including balance sheets, statements of operations, stockholders' equity, and cash flows for interim periods. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarterly and half-year data) confirms it is an interim financial report. The document also includes a notice of no auditor review, which is typical for interim financial statements. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-12 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis For the three and six months ended June 30, 2024' and contains detailed discussion of financial condition, results of operations, revenue, expenses, and recent business developments. It references unaudited condensed consolidated financial statements for the three and six months ended June 30, 2024 and 2023, indicating it is a quarterly or interim report. The content includes substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-12 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CEO of Evome Medical Technologies Inc. regarding the interim financial report and interim MD&A for the period ended June 30, 2024. It is a Form 52-109FV2 Venture Issuer Basic Certificate, which is a certification of interim filings. The document does not contain the actual interim financial statements or substantive financial data but is an attestation about the interim filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3029 characters), and it is primarily a certification letter, not the full interim report.
2024-08-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.